Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prepidil compared to Propess for cervical ripening.

A Vollebregt1, D B van't Hof, N Exalto

  • 1Department of Obstetrics and Gynaecology, Spaarne Ziekenhuis Haarlem, Afdeling Verloskunde en Gynaecologie, Postbus 1644, 2003 Haarlem BR, The Netherlands.

European Journal of Obstetrics, Gynecology, and Reproductive Biology
|September 11, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discontinuation of pessary therapy within 24 months: can it be predicted?

Archives of gynecology and obstetrics·2024
Same author

Pessary or surgery for a symptomatic pelvic organ prolapse: the PEOPLE study, a multicentre prospective cohort study.

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Authors' reply re: Hysteropexy in the treatment of uterine prolapse stage 2 or higher: laparoscopic sacrohysteropexy versus sacrospinous hysteropexy-a multicentre randomised controlled trial (LAVA trial).

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Hysteropexy in the treatment of uterine prolapse stage 2 or higher: laparoscopic sacrohysteropexy versus sacrospinous hysteropexy-a multicentre randomised controlled trial (LAVA trial).

BJOG : an international journal of obstetrics and gynaecology·2020
Same author

First-Trimester Crown-Rump Length and Embryonic Volume of Fetuses with Structural Congenital Abnormalities Measured in Virtual Reality: An Observational Study.

BioMed research international·2017
Same author

First trimester trophoblast and placental bed vascular volume measurements in IVF or IVF/ICSI pregnancies.

Human reproduction (Oxford, England)·2014

The intravaginal prostaglandin E(2) insert (Propess) was more effective for cervical ripening and labor induction than intracervical prostaglandin E(2) gel (Prepidil). Propess resulted in shorter intervals from application to membrane rupture and delivery, with fewer applications needed.

Area of Science:

  • Obstetrics and Gynecology
  • Reproductive Medicine
  • Pharmacology

Background:

  • Cervical ripening is crucial for labor induction.
  • Prostaglandin E(2) (PGE(2)) agents are commonly used for cervical ripening.
  • Comparing different formulations of PGE(2) is important for optimizing labor induction protocols.

Purpose of the Study:

  • To compare the efficacy and safety of intracervical PGE(2) gel (Prepidil) versus intravaginal PGE(2) insert (Propess) for cervical ripening and labor induction.
  • To evaluate key metrics such as time to cervical ripening, time to delivery, and number of applications required.

Main Methods:

  • Retrospective analysis of patients requiring cervical ripening.
  • Comparison of 50 consecutive patients receiving Prepidil (first half of 1998) versus 50 patients receiving Propess (first half of 1999).

Related Experiment Videos

  • Inclusion criteria: single pregnancy, intact membranes, viable fetus.

    • Main Results:

    • Propess achieved cervical ripening within 24 hours in 80% of patients, compared to 56% for Prepidil.
    • The interval from application to membrane rupture and delivery was significantly shorter with Propess.
    • Fewer applications of Propess were needed (1.2 vs. 1.8), and 62% of patients delivered within 24 hours with Propess versus 28% with Prepidil.

    Conclusions:

    • Both Prepidil and Propess are safe and effective for cervical ripening.
    • The intravaginal Propess insert demonstrated superior efficacy, leading to shorter delivery intervals and potentially reduced hospital stays and costs.
    • No significant differences in delivery mode or outcomes were observed between the two agents.